雌激素受体低表达在乳腺癌中的研究进展
Research Progress of Estrogen Receptor-Low Positive in Breast Cancer
DOI: 10.12677/ACM.2022.124483, PDF,   
作者: 刘 金, 明 佳*：重庆医科大学附属第二医院乳腺甲状腺外科，重庆
关键词: 乳腺癌；雌激素受体低表达；内分泌治疗；预后；Breast Cancer； ER-Low Positive； Endocrine Therapy； Prognosis
摘要: 雌激素受体(ER)状态对侵袭性乳腺癌患者的临床决策和预后预测起着重要的作用，因此激素受体检测主要用于指导乳腺癌患者的治疗选择。然而，确定ER状态和内分泌治疗资格的方法仍然存在争议。过去认为乳腺癌细胞核免疫组织化学染色ER ≥ 1%时即为ER阳性，但最新的指南将ER表达1%~10%的乳腺癌定义为“ER低表达”，这一亚组可能具有独特的分子特征，它与ER高表达的肿瘤相比，对内分泌疗法的治疗反应仍不清楚。最新的指南没有对这些患者提供详细的描述，导致治疗策略不一致。因此，我们对近期ER低表达的相关研究进行讨论分析，为ER低表达患者的临床管理提供可能的建议。
Abstract: Estrogen receptor (ER) status plays an important role in clinical decision-making and prognosis prediction of patients with invasive breast cancer, so hormone receptor detection is mainly used to guide the treatment selection of patients with breast cancer. However, the method of determining ER status and eligibility for endocrine therapy remains controversial. In the past, breast tumors with ER ≥ 1% on immunohistochemical staining of nuclei were considered ER-positive, but the latest guidelines define breast cancer with ER expression of 1%~10% as “ER-low positive”, which may have a unique molecular feature, and its response to endocrine therapy remains unclear compared with tumors with high ER expression. The latest guidelines do not provide a detailed description of these patients, leading to inconsistent treatment strategies. Therefore, we discuss and analyze the relevant studies of recent ER-low positive breast cancer to provide possible suggestions for the clinical management of patients with ER-low positive.
文章引用：刘金, 明佳. 雌激素受体低表达在乳腺癌中的研究进展[J]. 临床医学进展, 2022, 12(4): 3344-3349. https://doi.org/10.12677/ACM.2022.124483

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Yang, X.R., Chang-Claude, J., Goode, E.L., Couch, F.J., Nevanlinna, H., Milne, R.L., et al. (2011) Associations of Breast Cancer Risk Factors with Tumor Subtypes: A Pooled Analysis from the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 103, 250-263. [Google Scholar] [CrossRef] [PubMed]
[3] Munzone, E., Curigliano, G., Rocca, A., Bonizzi, G., Renne, G., Goldhirsch, A., et al. (2005) Reverting Estrogen-Receptor-Negative Phenotype in HER-2-Overexpressing Advanced Breast Cancer Patients Exposed to Trastuzumab Plus Chemotherapy. Breast Cancer Research, 8, Article No. R4. [Google Scholar] [CrossRef] [PubMed]
[4] Goldhirsch, A., Wood, W.C., Gelber, R.D., Coates, A.S., Thürlimann, B. and Senn, H.-J. (2003) Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. Journal of Clinical Oncology, 21, 3357-3365. [Google Scholar] [CrossRef] 
[5] Allison, K.H., Hammond, M.E.H., Dowsett, M., McKernin, S.E., Carey, L.A., Fitzgibbons, P.L., et al. (2020) Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology, 38, 1346-1366. [Google Scholar] [CrossRef] 
[6] Chen, T., Zhang, N., Moran, M.S., Su, P., Haffty, B.G. and Yang, Q. (2018) Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit from Endocrine Therapy: A Systematic Review and Meta-Analysis. Clinical Breast Cancer, 18, 1-8. [Google Scholar] [CrossRef] [PubMed]
[7] Collins, L.C., Botero, M.L. and Schnitt, S.J. (2005) Bimodal Frequency Distribution of Estrogen Receptor Immunohistochemical Staining Results in Breast Cancer. American Journal of Clinical Pathology, 123, 16-20. [Google Scholar] [CrossRef] 
[8] Peterson, T.J., Karmakar, S., Pace, M.C., Gao, T. and Smith, C.L. (2007) The Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) Corepressor Is Required for Full Estrogen Receptor α Transcriptional Activity. Molecular and Cellular Biology, 27, 5933-5948. [Google Scholar] [CrossRef] 
[9] Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., et al. (2007) Estrogen Receptors: How Do They Signal and What Are Their Targets. Physiological Reviews, 87, 905-931. [Google Scholar] [CrossRef] [PubMed]
[10] Ketchart, W., Ogba, N., Kresak, A., Albert, J.M., Pink, J.J. and Montano, M.M. (2011) HEXIM1 Is a Critical Determinant of the Response to Tamoxifen. Oncogene, 30, 3563-3569. [Google Scholar] [CrossRef] [PubMed]
[11] Sahab, Z.J., Man, Y.-G., Semaan, S.M., Newcomer, R.G., Byers, S.W. and Sang, Q.-X.A. (2010) Alteration in Protein Expression in Estrogen Receptor Alpha-Negative Human Breast Cancer Tissues Indicates a Malignant and Metastatic Phenotype. Clinical & Experimental Metastasis, 27, 493-503. [Google Scholar] [CrossRef] [PubMed]
[12] Rizza, P., Barone, I., Zito, D., Giordano, F., Lanzino, M., De Amicis, F., et al. (2014) Estrogen Receptor Beta as a Novel Target of Androgen Receptor Action in Breast Cancer Cell Lines. Breast Cancer Research, 16, Article ID: R21. [Google Scholar] [CrossRef] [PubMed]
[13] Hammond, M.E.H., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., et al. (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recom-mendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 28, 2784-2795. [Google Scholar] [CrossRef] 
[14] Yi, M., Huo, L., Koenig, K.B., Mittendorf, E.A., Meric-Bernstam, F., Kuerer, H.M., et al. (2014) Which Threshold for ER Positivity? A Retrospective Study Based on 9639 Patients. Annals of Oncology, 25, 1004-1011. [Google Scholar] [CrossRef] [PubMed]
[15] Harvey, J.M., Clark, G.M., Osborne, C.K. and Allred, D.C. (1999) Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 17. 1471-1481. [Google Scholar] [CrossRef] 
[16] Poon, I.K., Tsang, J.Y., Li, J., Chan, S., Shea, K. and Tse, G.M. (2020) The Significance of Highlighting the Oestrogen Receptor Low Category in Breast Cancer. British Journal of Cancer, 123, 1223-1227. [Google Scholar] [CrossRef] [PubMed]
[17] Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., et al. (2011) Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-Analysis of Randomised Trials. Lancet, 378, 771-784. [Google Scholar] [CrossRef] 
[18] Fujii, T., Kogawa, T., Dong, W., Sahin, A.A., Moulder, S., Litton, J.K., et al. (2017) Revisiting the Definition of Estrogen Receptor Positivity in HER2-Negative Primary Breast Cancer. Annals of Oncology, 28, 2420-2428. [Google Scholar] [CrossRef] [PubMed]
[19] DeCensi, A., Puntoni, M., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L., et al. (2019) Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. Journal of Clinical Oncology, 37, 1629-1637. [Google Scholar] [CrossRef] 
[20] The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-Month analysis of the ATAC Trial. The Lancet Oncology, 9, 45-53. [Google Scholar] [CrossRef] 
[21] Keen, J.C. and Davidson, N.E. (2003) The Biology of Breast Carcinoma. Cancer, 97, 825-833. [Google Scholar] [CrossRef] [PubMed]
[22] Ellis, M.J., Llombart-Cussac, A., Feltl, D., Dewar, J.A., Jasiówka, M., Hewson, N., et al. (2015) Fulvestrant 500 mg versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis from the Phase II FIRST Study. Journal of Clinical Oncology, 33, 3781-3787. [Google Scholar] [CrossRef] 
[23] Yu, K., Cai, Y., Wu, S., Shui, R. and Shao Z. (2021) Estrogen Receptor-Low Breast Cancer: Biology Chaos and Treatment Paradox. Cancer Communications, 41, 968-980. [Google Scholar] [CrossRef] [PubMed]
[24] Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., et al. (2017) Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine, 376, 2147-2159. [Google Scholar] [CrossRef] 
[25] Colleoni, M., Gray, K.P., Gelber, S., Láng, I., Thürlimann, B., Gianni, L., et al. (2016) Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Recep-tor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. Journal of Clinical Oncolog, 34, 3400-3408. [Google Scholar] [CrossRef] 
[26] Iwase, H., Greenman, J., Barnes, D., Bobrow, L., Hodgson, S. and Mathew, C. (1995) Loss of Heterozygosity of the Oestrogen Receptor Gene in Breast Cancer. British Journal of Cancer, 71, 448-450. [Google Scholar] [CrossRef] [PubMed]
[27] Tsuboi, K., Nagatomo, T., Gohno, T., Higuchi, T., Sasaki, S., Fujiki, N., et al. (2017) Single CpG Site Methylation Controls Estrogen Receptor Gene Transcription and Correlates with Hormone Therapy Resistance. The Journal of Steroid Biochemistry and Molecular Biology, 171, 209-217. [Google Scholar] [CrossRef] [PubMed]
[28] Mansoori, B., Mohammadi, A., Gjerstorff, M.F., Shirjang, S., Asadzadeh, Z., Khaze, V., et al. (2019) miR-142-3p Is a Tumor Suppressor That Inhibits Estrogen Receptor Expression in ER-Positive Breast Cancer. Journal of Cellular Physiology, 234, 16043-16053. [Google Scholar] [CrossRef] [PubMed]
[29] Li, L., Li, Z., Howley, P.M. and Sacks, D.B. (2006) E6AP and Calmodulin Reciprocally Regulate Estrogen Receptor Stability. Journal of Biological Chemistry, 281, 1978-1985. [Google Scholar] [CrossRef] 
[30] Oh, A.S., Lorant, L.A., Holloway, J.N., Miller, D.L., Kern, F.G. and El-Ashry, D. (2001) Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells. Molecular Endocrinology, 15, 1344-1359. [Google Scholar] [CrossRef] [PubMed]

为你推荐